European Commision (EC) has approved Horizon’s Uplizna as a monotherapy in adults for the treatment of Neuromyelitis optica spectrum disorder (NMOSD), a disease affecting the central nervous system (CNS), specifically the optic and spinal nerve. The treatment is viable for NMSOD patients who are anti-aquaporin-4 immunoglobulin G seropositive. Following the preliminary doses, experiments explicated that Uplizna greatly reduced NMOSD attacks with two infusions per year. 87.6% of the subjects chosen for trial remained attack free for 28 weeks. After EC’s nod, Uplizna is fit to be used in all European states as well as Iceland, Liechtenstein and Norway.
Read More from Pharmaceutical Technology